Does cost effectiveness analysis really need to abandon the incremental cost effectiveness ratio to embrace net benefit?

PharmacoEconomics

10 July 2020 - The central task of cost-effectiveness analysis is to identify strategies that maximise health within finite budgets. 

Paulden notes that the incremental cost effectiveness ratio and net benefit perform this task equally well. He outlines the advantages net benefit has, both in terms of being easier to calculate and interpret as well as informing decision makers beyond simply picking the optimal strategy.

Net benefit undoubtedly has important advantages over incremental cost effectiveness ratios and these have been ably articulated by Paulden.

Read PharmacoEconomics Editorial

Michael Wonder

Posted by:

Michael Wonder